The drug is used for the treatment of oncological patients at the advanced disease stages to improve quality of life; it may be recommended for the patients with chemo-resistant tumors, as well as in cases when all chemotherapy possibilities are exhausted.

Segidrin® significantly reduces (more than 50%) pain syndrome pending refusal of opioid pain medicines. Its efficacy is confirmed by clinical trials. Over the years of its existence in the market, Segidrin® proved itself to be good in the Russian clinical practice and is in stable demand. Since 2018, an “upgraded” version of the drug with an improved tablet coating increasing active ingredient bioavailability is produced.

Vikram Punia, President of the Pharmasyntez Group, is convinced that the Russian Segidrin® drug product is of high commercial potential. In addition, he expressed the hope that the partnership with respect to future innovation projects by and between the Pharmasyntez Group and PJSC Pharmsynthez will continue.